Objective To explore the preventive effect of beraprost sodium on the basis of conventional treatment on contrast-induced nephropathy (CIN) in patients with coronary heart disease after percutaneous coronary intervention (PCI). Methods A total of 279 patients with coronary heart disease undergoing percutaneous coronary intervention (PCI) were randomly divided into beraprost sodium group (treatment group, n=140) and conventional therapy group (control group, n=139). Control group were given conventional antiplatelet, anticoagulation, lipid-lowering and hydration therapy, and based on it, the treatment group was treated with beraprost sodium oral 40μg, 3 times a day, 3-5 days before opration. All the patients were measured serum creatinine (Scr) and urinary neutrophil gelatinase-associated lipocalin (NGAL), calculated glomerular filtration rate (GFR) before and after opration. Comparison of incidence rate of two groups of patients with CIN. Results Levels of Scr and eGFR showed no significantly differences between these two groups (P>0.05). Two groups of patients had 20 cases (7.1%) contrast-induced nephropathy, including the basis of the treatment group of 15 cases (10.8%), treatment group of 5 cases (3.6%). The incidence of contrast-induced nephropathy was significantly different between these two groups (P<0.05). Conclusion On acute kidney injury caused to contrast medium ,the incidence of CIN was lowed when beraprost sodium is used.%目的：探讨在常规治疗的基础上加用贝前列素钠能对冠心病患者经皮冠状动脉介入治疗术(PCI)后对比剂肾病（CIN）的预防作用。方法对住院拟行冠脉介入治疗的冠心病患者279例，随机分为贝前列素钠组（治疗组，n=140例）和基础治疗组（对照组，n=139例）。基础治疗组常规给予抗血小板、抗凝、调脂及水化等治疗。治疗组在常规治疗基础上PCI术前3~5d口服贝前列素钠40μg，3次/天。所有患者测定术前、术后血清肌酐（Scr）及尿液尿中性粒细胞明胶酶脂质运载蛋白（NGAL），计算肾小球滤过率（GFR）。比较两组患者CIN的发生率。结果两组患者的年龄、性别构成、吸烟率、体质指数，高血压、高脂血症、糖尿病病史发生率，碘海醇用量、血红蛋白（Hb）、空腹血糖（FBG）、eGFR均无统计学意义（P＞0.05）。两组患者共发生造影剂肾病20例（7.1%），其中基础治疗组15例（10.8%），治疗组组5例（3.6%），两组造影剂肾病的发生率具有统计学意义（P<0.05）。结论对于对比剂引发的急性肾损伤，在常规治疗的基础上加用贝前列素钠可以有效地预防对比剂肾病的发生。
展开▼
